Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.

ClinicalTrials.gov ID: NCT02296138

Public ClinicalTrials.gov record NCT02296138. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 3:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomised, Double-blind, Active-controlled Parallel Group Study to Evaluate the Effect of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared With Tiotropium on Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Patients With Severe to Very Severe COPD. [DYNAGITO]

Study identification

NCT ID
NCT02296138
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Boehringer Ingelheim
Industry
Enrollment
7,903 participants

Conditions and interventions

Interventions

  • olodaterol Drug
  • tiotropium Drug

Drug

Eligibility (public fields only)

Age range
40 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 12, 2015
Primary completion
Mar 7, 2017
Completion
Mar 28, 2017
Last update posted
Jun 3, 2018

2015 – 2017

United States locations

U.S. sites
117
U.S. states
35
U.S. cities
103
Facility City State ZIP Site status
1237.19.10039 Boehringer Ingelheim Investigational Site Andalusia Alabama
1237.19.10009 Boehringer Ingelheim Investigational Site Birmingham Alabama
1237.19.10077 Boehringer Ingelheim Investigational Site Florence Alabama
1237.19.10115 Boehringer Ingelheim Investigational Site Jasper Alabama
1237.19.10069 Boehringer Ingelheim Investigational Site Flagstaff Arizona
1237.19.10085 Boehringer Ingelheim Investigational Site Peoria Arizona
1237.19.10110 Boehringer Ingelheim Investigational Site Lincoln California
1237.19.10118 Boehringer Ingelheim Investigational Site Los Angeles California
1237.19.10074 Boehringer Ingelheim Investigational Site Poway California
1237.19.10157 Boehringer Ingelheim Investigational Site Lafayette Colorado
1237.19.10142 Boehringer Ingelheim Investigational Site Wheat Ridge Colorado
1237.19.10133 Boehringer Ingelheim Investigational Site Norwalk Connecticut
1237.19.10093 Boehringer Ingelheim Investigational Site Stamford Connecticut
1237.19.10029 Boehringer Ingelheim Investigational Site Clearwater Florida
1237.19.10106 Boehringer Ingelheim Investigational Site Clearwater Florida
1237.19.10020 Boehringer Ingelheim Investigational Site Orlando Florida
1237.19.10000 Boehringer Ingelheim Investigational Site St. Petersburg Florida
1237.19.10135 Boehringer Ingelheim Investigational Site St. Petersburg Florida
1237.19.10145 Boehringer Ingelheim Investigational Site Tamarac Florida
1237.19.10066 Boehringer Ingelheim Investigational Site Tampa Florida
1237.19.10032 Boehringer Ingelheim Investigational Site Winter Park Florida
1237.19.10080 Boehringer Ingelheim Investigational Site Duluth Georgia
1237.19.10011 Boehringer Ingelheim Investigational Site Gainesville Georgia
1237.19.10112 Boehringer Ingelheim Investigational Site Lawrenceville Georgia
1237.19.10037 Boehringer Ingelheim Investigational Site Eagle Idaho
1237.19.10130 Boehringer Ingelheim Investigational Site O'Fallon Illinois
1237.19.10065 Boehringer Ingelheim Investigational Site River Forest Illinois
1237.19.10122 Boehringer Ingelheim Investigational Site Muncie Indiana
1237.19.10063 Boehringer Ingelheim Investigational Site Topeka Kansas
1237.19.10048 Boehringer Ingelheim Investigational Site Bowling Green Kentucky
1237.19.10108 Boehringer Ingelheim Investigational Site Fort Mitchell Kentucky
1237.19.10109 Boehringer Ingelheim Investigational Site New Orleans Louisiana
1237.19.10095 Boehringer Ingelheim Investigational Site Opelousas Louisiana
1237.19.10113 Boehringer Ingelheim Investigational Site Shreveport Louisiana
1237.19.10139 Boehringer Ingelheim Investigational Site Shreveport Louisiana
1237.19.10117 Boehringer Ingelheim Investigational Site Baltimore Maryland
1237.19.10083 Boehringer Ingelheim Investigational Site Columbia Maryland
1237.19.10072 Boehringer Ingelheim Investigational Site Hollywood Maryland
1237.19.10027 Boehringer Ingelheim Investigational Site Fall River Massachusetts
1237.19.10138 Boehringer Ingelheim Investigational Site North Dartmouth Massachusetts
1237.19.10103 Boehringer Ingelheim Investigational Site Worcester Massachusetts
1237.19.10075 Boehringer Ingelheim Investigational Site Ann Arbor Michigan
1237.19.10034 Boehringer Ingelheim Investigational Site Farmington Hills Michigan
1237.19.10082 Boehringer Ingelheim Investigational Site Traverse City Michigan
1237.19.10043 Boehringer Ingelheim Investigational Site Fridley Minnesota
1237.19.10096 Boehringer Ingelheim Investigational Site Rochester Minnesota
1237.19.10031 Boehringer Ingelheim Investigational Site Chesterfield Missouri
1237.19.10101 Boehringer Ingelheim Investigational Site Saint Charles Missouri
1237.19.10051 Boehringer Ingelheim Investigational Site St Louis Missouri
1237.19.10084 Boehringer Ingelheim Investigational Site St Louis Missouri
1237.19.10097 Boehringer Ingelheim Investigational Site Missoula Montana
1237.19.10060 Boehringer Ingelheim Investigational Site Reno Nevada
1237.19.10081 Boehringer Ingelheim Investigational Site Marlton New Jersey
1237.19.10094 Boehringer Ingelheim Investigational Site Brooklyn New York
1237.19.10137 Boehringer Ingelheim Investigational Site Larchmont New York
1237.19.10143 Boehringer Ingelheim Investigational Site Syracuse New York
1237.19.10035 Boehringer Ingelheim Investigational Site Burlington North Carolina
1237.19.10014 Boehringer Ingelheim Investigational Site Calabash North Carolina
1237.19.10098 Boehringer Ingelheim Investigational Site Charlotte North Carolina
1237.19.10131 Boehringer Ingelheim Investigational Site Charlotte North Carolina
1237.19.10049 Boehringer Ingelheim Investigational Site Elizabeth City North Carolina
1237.19.10154 Boehringer Ingelheim Investigational Site Gastonia North Carolina
1237.19.10104 Boehringer Ingelheim Investigational Site Hickory North Carolina
1237.19.10087 Boehringer Ingelheim Investigational Site Huntersville North Carolina
1237.19.10053 Boehringer Ingelheim Investigational Site Shelby North Carolina
1237.19.10062 Boehringer Ingelheim Investigational Site Wilmington North Carolina
1237.19.10008 Boehringer Ingelheim Investigational Site Cincinnati Ohio
1237.19.10042 Boehringer Ingelheim Investigational Site Cincinnati Ohio
1237.19.10127 Boehringer Ingelheim Investigational Site Columbus Ohio
1237.19.10121 Boehringer Ingelheim Investigational Site Dayton Ohio
1237.19.10148 Boehringer Ingelheim Investigational Site Dayton Ohio
1237.19.10005 Boehringer Ingelheim Investigational Site Delaware Ohio
1237.19.10147 Boehringer Ingelheim Investigational Site Kettering Ohio
1237.19.10055 Boehringer Ingelheim Investigational Site Toledo Ohio
1237.19.10146 Boehringer Ingelheim Investigational Site Tulsa Oklahoma
1237.19.10021 Boehringer Ingelheim Investigational Site Medford Oregon
1237.19.10129 Boehringer Ingelheim Investigational Site Erie Pennsylvania
1237.19.10140 Boehringer Ingelheim Investigational Site Oaks Pennsylvania
1237.19.10003 Boehringer Ingelheim Investigational Site Philadelphia Pennsylvania
1237.19.10019 Boehringer Ingelheim Investigational Site Philadelphia Pennsylvania
1237.19.10006 Boehringer Ingelheim Investigational Site Pittsburgh Pennsylvania
1237.19.10136 Boehringer Ingelheim Investigational Site Pittsburgh Pennsylvania
1237.19.10151 Boehringer Ingelheim Investigational Site Pittsburgh Pennsylvania
1237.19.10041 Boehringer Ingelheim Investigational Site East Providence Rhode Island
1237.19.10126 Boehringer Ingelheim Investigational Site Johnston Rhode Island
1237.19.10054 Boehringer Ingelheim Investigational Site Charleston South Carolina
1237.19.10086 Boehringer Ingelheim Investigational Site Columbia South Carolina
1237.19.10058 Boehringer Ingelheim Investigational Site Easley South Carolina
1237.19.10023 Boehringer Ingelheim Investigational Site Gaffney South Carolina
1237.19.10030 Boehringer Ingelheim Investigational Site Gaffney South Carolina
1237.19.10024 Boehringer Ingelheim Investigational Site Greenville South Carolina
1237.19.10128 Boehringer Ingelheim Investigational Site Greenville South Carolina
1237.19.10144 Boehringer Ingelheim Investigational Site Mt. Pleasant South Carolina
1237.19.10071 Boehringer Ingelheim Investigational Site Myrtle Beach South Carolina
1237.19.10099 Boehringer Ingelheim Investigational Site Old Point Station South Carolina
1237.19.10025 Boehringer Ingelheim Investigational Site Rock Hill South Carolina
1237.19.10033 Boehringer Ingelheim Investigational Site Spartanburg South Carolina
1237.19.10036 Boehringer Ingelheim Investigational Site Spartanburg South Carolina
1237.19.10010 Boehringer Ingelheim Investigational Site Union South Carolina
1237.19.10007 Boehringer Ingelheim Investigational Site Rapid City South Dakota
1237.19.10070 Boehringer Ingelheim Investigational Site Boerne Texas
1237.19.10107 Boehringer Ingelheim Investigational Site Corsicana Texas
1237.19.10153 Boehringer Ingelheim Investigational Site Fort Worth Texas
1237.19.10047 Boehringer Ingelheim Investigational Site Houston Texas
1237.19.10111 Boehringer Ingelheim Investigational Site Killeen Texas
1237.19.10059 Boehringer Ingelheim Investigational Site Kingwood Texas
1237.19.10061 Boehringer Ingelheim Investigational Site McKinney Texas
1237.19.10050 Boehringer Ingelheim Investigational Site San Antonio Texas
1237.19.10091 Boehringer Ingelheim Investigational Site Abingdon Virginia
1237.19.10076 Boehringer Ingelheim Investigational Site Lynchburg Virginia
1237.19.10040 Boehringer Ingelheim Investigational Site Richmond Virginia
1237.19.10089 Boehringer Ingelheim Investigational Site Richmond Virginia
1237.19.10123 Boehringer Ingelheim Investigational Site Everett Washington
1237.19.10120 Boehringer Ingelheim Investigational Site Spokane Washington
1237.19.10092 Boehringer Ingelheim Investigational Site Tacoma Washington
1237.19.10001 Boehringer Ingelheim Investigational Site Morgantown West Virginia
1237.19.10016 Boehringer Ingelheim Investigational Site West Allis Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 701 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02296138, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 3, 2018 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02296138 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →